Edited by three of the world's leading pharmaceutical scientists, this is the first book on this important and hot topic, containing much previously unpublished information. As such, it covers all aspects of green chemistry in the pharmaceutical industry, from simple molecules to complex proteins, and from drug discovery to the fate of pharmaceuticals in the environment. Furthermore, this ready reference contains several convincing case studies from industry, such as Taxol, Pregabalin and Crestor, illustrating how this multidisciplinary approach has yielded efficient and environmentally-friendly processes. Finally, a section on technology and tools highlights the advantages of green chemistry.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Understanding how to apply the principles of green chemistry into a vital area such as pharmaceuticals is the overall goal of this monograph. Edited by three of the world?s leading pharmaceutical scientists, this is the first book to collate much previously unpublished information into one resource. It handles all aspects of green chemistry in the pharmaceutical industry, from simple molecules to complex proteins, and from drug discovery to the fate of pharmaceuticals in the environment. This ready reference contains several case studies direct from industry, such as Taxol, Pregabalin and Crestor, illustrating how this multidisciplinary approach has yielded efficient and environmentally-friendly processes. Regulations and safety matters are discussed for the processes being described.
This monograph includes a Foreword by Steven V. Ley (University of Cambridge, UK).
Peter Dunn received his PhD from Imperial College London in 1987 working under the supervision of Professor Charles Rees. Postdoctoral work followed with Prof. Albert Eschenmoser at the ETH, Zurich and with Prof. Henry Rapaport at the University of California, Berkeley. In 1989 he joined Pfizer and was involved with the invention of the commercial processes to make several medicines including "Viagra", Emselex, Revation and Sampatrilat. In 2000 he became Director of Chemical R & D at Pfizer and was responsible for the filing and transfer to manufacturing of human and animal medicines such as Voriconazole, Darifenacin, Fosfluconazole and Dirlotapide. In 2006 he took up his current role as Global Green Chemistry lead for Pfizer. He is currently co-chair of the Green Chemistry Institute Pharmaceutical Roundtable and a member of the editorial board for the journal of Green Chemistry.
Andrew Wells obtained his PhD in organophosphorous and organometallic chemistry from Essex University, before joining the Chemical Development Group of SmithKline & French in 1986, which later became SmithKline Beecham. In 1999 he received a SKB corporate award for green chemistry/technology. In 2000, he joined AstraZeneca in Global Process R & D where he is currently a Senior Principal Scientist and heads the AZ GPRD Green Chemistry group. He is an active member of the ACS Green Chemistry Institute Pharmaceutical Roundtable and has acted as an advisor to the UK Chemical Innovation Knowledge Transfer Network and the UK Technology Strategy Board. A keen supporter of the industry-academia interface, having been involved closely with several major collaborations such as the Centre for Biocatalysis at Manchester and the Institute of Process R & D at Leeds University, he has also been an industrial supervisor to around 20 PhD and MSc students.
Michael Williams obtained his chemistry BSc from King's College, London, and spent time as a medicinal chemist at ICI Pharmaceuticals (Alderley Park), before obtaining his PhD working with Professor Charles Rees at the University of Liverpool. He joined the Chemical R & D department at Pfizer at Sandwich in 1972, where his career responsibilities included the Medicinal Chemistry/Development interface, and technology adoption. In addition to his experience with approximately 50 early drug candidates, he played a significant role in the late development, filing and commercializing of many agents including Zoloft, Viagra and Relpax. He became Executive Director and Departmental Head of UK Chemical R & D in 2003, leading a significant growth to 117 laboratory staff, and helping to build a 40 strong Material Sciences group. Since retiring from Pfizer in 2007, he has been an independent consultant, in addition to his work in editing and scientific writing.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Description du livre État : Brand New. Brand New Original US Edition, Perfect Condition. Printed in English. Excellent Quality, Service and customer satisfaction guaranteed!. N° de réf. du libraire AIND-5248
Description du livre Wiley VCH, 2010. HRD. État : New. New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. N° de réf. du libraire FW-9783527324187
Description du livre État : New. Brand New Original US Edition.We Ship to PO BOX Address also. EXPEDITED shipping option also available for faster delivery. N° de réf. du libraire AUSBNEW-5248
Description du livre État : New. New. US edition. Perfect condition. Customer satisfaction our priority. N° de réf. du libraire ABE-FEB-120939
Description du livre État : Brand New. New. US edition. Customer Satisfaction guaranteed!!. N° de réf. du libraire SHUB120939
Description du livre État : Brand New. New, US edition. Excellent Customer Service. N° de réf. du libraire ABEUSA-120939
Description du livre Wiley-VCH. Hardcover. État : New. 3527324186 Brand New Book in Perfect Condition.Fast Shipping with tracking number. N° de réf. du libraire KADA-DBSPD-6183
Description du livre Wiley-VCH 2010-03-10, Weinheim, 2010. hardback. État : New. N° de réf. du libraire 9783527324187
Description du livre John Wiley and Sons. État : New. Brand New. N° de réf. du libraire 3527324186
Description du livre John Wiley & Sons. État : New. pp. 388. N° de réf. du libraire 8293450